Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens.

Delville M, Lamarthée B, Pagie S, See SB, Rabant M, Burger C, Gatault P, Giral M, Thaunat O, Arzouk N, Hertig A, Hazzan M, Matignon M, Mariat C, Caillard S, Kamar N, Sayegh J, Westeel PF, Garrouste C, Ladrière M, Vuiblet V, Rivalan J, Merville P, Bertrand D, Le Moine A, Van Huyen JPD, Cesbron A, Cagnard N, Alibeu O, Satchell SC, Legendre C, Zorn E, Taupin JL, Charreau B, Anglicheau D.

J Am Soc Nephrol. 2019 Apr;30(4):692-709. doi: 10.1681/ASN.2018080868. Epub 2019 Mar 8.

PMID:
30850439
2.

Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide.

Willem C, Makanga DR, Guillaume T, Maniangou B, Legrand N, Gagne K, Peterlin P, Garnier A, Béné MC, Cesbron A, Le Bourgeois A, Chevallier P, Retière C.

J Immunol. 2019 Apr 1;202(7):2141-2152. doi: 10.4049/jimmunol.1801489. Epub 2019 Feb 20.

PMID:
30787107
3.

Quality control project of NGS HLA genotyping for the 17th International HLA and Immunogenetics Workshop.

Osoegawa K, Vayntrub TA, Wenda S, De Santis D, Barsakis K, Ivanova M, Hsu S, Barone J, Holdsworth R, Diviney M, Askar M, Willis A, Railton D, Laflin S, Gendzekhadze K, Oki A, Sacchi N, Mazzocco M, Andreani M, Ameen R, Stavropoulos-Giokas C, Dinou A, Torres M, Dos Santos Francisco R, Serra-Pages C, Goodridge D, Balladares S, Bettinotti MP, Iglehart B, Kashi Z, Martin R, Saw CL, Ragoussis J, Downing J, Navarrete C, Chong W, Saito K, Petrek M, Tokic S, Padros K, Beatriz Rodriguez M, Zakharova V, Shragina O, Marino SR, Brown NK, Shiina T, Suzuki S, Spierings E, Zhang Q, Yin Y, Morris GP, Hernandez A, Ruiz P, Khor SS, Tokunaga K, Geretz A, Thomas R, Yamamoto F, Mallempati KC, Gangavarapu S, Kanga U, Tyagi S, Marsh SGE, Bultitude WP, Liu X, Cao D, Penning M, Hurley CK, Cesbron A, Mueller C, Mytilineos J, Weimer ET, Bengtsson M, Fischer G, Hansen JA, Chang CJ, Mack SJ, Creary LE, Fernandez-Viña MA.

Hum Immunol. 2019 Apr;80(4):228-236. doi: 10.1016/j.humimm.2019.01.009. Epub 2019 Feb 6. Review.

4.

HLA-DRB3/4/5 mismatches are associated with increased risk of acute GVHD in 10/10 matched unrelated donor hematopoietic cell transplantation.

Ducreux S, Dubois V, Amokrane K, Yakoub-Agha I, Labalette M, Michallet M, Rubio MT, Kennel A, Forcade E, Lafarge X, Bulabois CE, Masson D, Daguindau E, Devys A, Moalic V, Quelvennec E, Boudifa A, Picard C, Van Endert P, de Matteis M, Delbos F, Filloux M, Pedron B, Renac V, Hau F, Bonneau J, Parissiadis A, Fort M, Dormoy A, Maillard N, Jollet I, Chevallier P, Cesbron A, Bay JO, Quainon F, Garnier F, Socié G, Loiseau P, Porcher R, Peffault de Latour R; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).

Am J Hematol. 2018 May 4. doi: 10.1002/ajh.25133. [Epub ahead of print]

5.

Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation.

Mai HL, Treilhaud M, Ben-Arye SL, Yu H, Perreault H, Ang E, Trébern-Launay K, Laurent J, Malard-Castagnet S, Cesbron A, Nguyen TVH, Brouard S, Rostaing L, Houssel-Debry P, Legendre C, Girerd S, Kessler M, Morelon E, Sicard A, Garrigue V, Karam G, Chen X, Giral M, Padler-Karavani V, Soulillou JP.

Transplant Direct. 2018 Mar 20;4(4):e357. doi: 10.1097/TXD.0000000000000772. eCollection 2018 Apr.

6.

Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide.

Garnier A, Delbos F, Guillaume T, Peterlin P, Le Bourgeois A, Béné MC, Le Bris Y, Malard S, Duquesne A, Gauvrit I, Moreau P, Cesbron A, Chevallier P.

Bone Marrow Transplant. 2018 Aug;53(8):1044-1047. doi: 10.1038/s41409-018-0107-7. Epub 2018 Feb 1. No abstract available.

PMID:
29391525
7.

[Caracterization of HLA allo-immunization and clinical impact in transfusion and organ transplantation].

Delbos F, Cesbron A.

Transfus Clin Biol. 2017 Sep;24(3):131-137. doi: 10.1016/j.tracli.2017.06.025. Epub 2017 Jul 28. Review. French.

PMID:
28757117
8.

Hazardous Drug Diversion of Valproate from a General Practitioner to his Patient's Dog.

Morice PM, Alexandre J, Cesbron A, Sassier M, Fedrizzi S, Humbert X.

Drug Saf Case Rep. 2017 Dec;4(1):8. doi: 10.1007/s40800-017-0050-3.

9.

[Polymorphism in HLA and KIR genes and the impact on hematopoietic stem cell transplantation outcomes and unrelated donor selection: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].

Dubois V, Brignier A, Elsermans V, Gagne K, Kennel A, Pedron B, Picard C, Ravinet A, Varlet P, Cesbron A, Delbos F, Yakoub-Agha I, Loiseau P.

Bull Cancer. 2016 Nov;103(11S):S243-S247. doi: 10.1016/j.bulcan.2016.09.005. Epub 2016 Nov 14. French.

PMID:
27855950
10.

Cardiac arrests associated with low plasma and tissue levels of local anaesthetics.

Alexandre J, Humbert X, Sassier M, Cesbron A, Le Naourès C, Pottier V, Puddu PE, Milliez P, Coquerel A, Fedrizzi S.

Therapie. 2016 Oct 8. pii: S0040-5957(16)31134-9. doi: 10.2515/therapie/2015056. [Epub ahead of print] No abstract available.

PMID:
27839711
11.

Impact of Graft-Versus-Graft Natural Killer Cell Alloreactivity on Single Unit Dominance After Double Umbilical Cord Blood Transplantation.

Rettman P, Willem C, Volteau C, Legrand N, Chevallier P, Lodé L, Esbelin J, Cesbron A, Bonneville M, Moreau P, Senitzer D, Retière C, Gagne K.

Transplantation. 2017 Sep;101(9):2092-2101. doi: 10.1097/TP.0000000000001545.

PMID:
27798515
12.

Impact of KIR/HLA genetic combinations on double umbilical cord blood transplantation outcomes. Results of a French multicentric retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) and the Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI).

Rettman P, Malard F, Legrand N, Avinens O, Eliaou JF, Picard C, Dormoy A, Lafarge X, de Matteis M, Kennel A, Loiseau P, Devys A, Boudifa A, Absi L, Fort M, Masson D, Quainon F, Theodorou I, Batho A, Parissiadis A, Delbos F, Drouet M, Senitzer D, Marry E, Raus N, Yakoub-Agha I, Cesbron A, Retière C, Gagne K.

Bone Marrow Transplant. 2016 Nov;51(11):1499-1503. doi: 10.1038/bmt.2016.151. Epub 2016 Jun 6. No abstract available.

PMID:
27272444
13.

Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients.

Dugast E, Soulillou JP, Foucher Y, Papuchon E, Guerif P, Paul C, Riochet D, Chesneau M, Cesbron A, Renaudin K, Dantal J, Giral M, Brouard S.

Am J Transplant. 2016 Nov;16(11):3255-3261. doi: 10.1111/ajt.13946. Epub 2016 Jul 29.

14.

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.

Carapito R, Jung N, Kwemou M, Untrau M, Michel S, Pichot A, Giacometti G, Macquin C, Ilias W, Morlon A, Kotova I, Apostolova P, Schmitt-Graeff A, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Lafarge X, Maumy-Bertrand M, Bertrand F, Vago L, Ciceri F, Paillard C, Querol S, Sierra J, Fleischhauer K, Nagler A, Labopin M, Inoko H, von dem Borne PA, Kuball J, Ota M, Katsuyama Y, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Milpied N, Charron D, Mohty M, Zeiser R, Socié G, Bahram S.

Blood. 2016 Oct 13;128(15):1979-1986. Epub 2016 Aug 22.

15.

Multidimensional reduction of multicentric cohort heterogeneity: An alternative method to increase statistical power and robustness.

Le Gall C, Laurent J, Vince N, Lizee A, Agrawal A, Walencik A, Rettman P, Gagne K, Retiere C, Hollenbach J, Cesbron A, Limou S, Gourraud PA.

Hum Immunol. 2016 Nov;77(11):1024-1029. doi: 10.1016/j.humimm.2016.05.013. Epub 2016 Jun 1.

PMID:
27262455
16.

New insights on the natural killer cell repertoire from a thorough analysis of cord blood cells.

Rettman P, Willem C, David G, Riou R, Legrand N, Esbelin J, Cesbron A, Senitzer D, Gagne K, Retière C.

J Leukoc Biol. 2016 Sep;100(3):471-9. doi: 10.1189/jlb.1HI0116-036R. Epub 2016 Apr 11.

PMID:
27067451
17.

Sialylation of antibodies in kidney recipients with de novo donor specific antibody, with or without antibody mediated rejection.

Malard-Castagnet S, Dugast E, Degauque N, Pallier A, Soulillou JP, Cesbron A, Giral M, Harb J, Brouard S.

Hum Immunol. 2016 Nov;77(11):1076-1083. doi: 10.1016/j.humimm.2015.10.021. Epub 2015 Nov 10.

PMID:
26546874
18.

Cardiac Arrests Associated with Low Plasma and Tissue Levels of Local Anaesthetics.

Alexandre J, Humbert X, Sassier M, Cesbron A, Le Naourès C, Pottier V, Puddu PE, Milliez P, Coquerel A, Fedrizzi S.

Therapie. 2015 Oct 16. [Epub ahead of print]

PMID:
26475751
19.

Use of killer cell immunoglobulin-like receptor genes as early markers of hematopoietic chimerism after double-umbilical cord blood transplantation.

Rettman P, Legrand N, Willem C, Lodé L, Chevallier P, Cesbron A, Senitzer D, Retière C, Gagne K.

Haematologica. 2015 Nov;100(11):e475-9. doi: 10.3324/haematol.2015.127993. Epub 2015 Jul 23. No abstract available.

20.

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.

Maïga S, Brosseau C, Descamps G, Dousset C, Gomez-Bougie P, Chiron D, Ménoret E, Kervoelen C, Vié H, Cesbron A, Moreau-Aubry A, Amiot M, Pellat-Deceunynck C.

Cytometry A. 2015 Apr;87(4):285-8. doi: 10.1002/cyto.a.22643. Epub 2015 Feb 16. No abstract available.

21.

Is there any impact of HLA-DPB1 disparity in 10/10 HLA-matched unrelated hematopoietic SCT? Results of a French multicentric retrospective study.

Gagne K, Loiseau P, Dubois V, Dufossé F, Perrier P, Dormoy A, Jollet I, Renac V, Masson D, Picard C, Lafarge X, Hanau D, Quainon F, Delbos F, Coeffic B, Absi L, Eliaou JF, Moalic V, Fort M, de Matteis M, Theodorou I, Hau F, Batho A, Pedron B, Caillat-Zucman S, Marry E, Raus N, Yakoub-Agha I, Cesbron A.

Bone Marrow Transplant. 2015 Feb;50(2):232-6. doi: 10.1038/bmt.2014.253. Epub 2014 Nov 3.

PMID:
25365066
22.

HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation.

Petersdorf EW, Gooley TA, Malkki M, Bacigalupo AP, Cesbron A, Du Toit E, Ehninger G, Egeland T, Fischer GF, Gervais T, Haagenson MD, Horowitz MM, Hsu K, Jindra P, Madrigal A, Oudshoorn M, Ringdén O, Schroeder ML, Spellman SR, Tiercy JM, Velardi A, Witt CS, O'Huigin C, Apps R, Carrington M; International Histocompatibility Working Group in Hematopoietic Cell Transplantation.

Blood. 2014 Dec 18;124(26):3996-4003. doi: 10.1182/blood-2014-09-599969. Epub 2014 Oct 16.

23.

Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults.

Le Bourgeois A, Labopin M, Guillaume T, Delaunay J, Foucher Y, Tessoulin B, Malard F, Ayari S, Peterlin P, Derenne S, Herry P, Cesbron A, Gagne K, Lodé L, Illiaquer M, Imbert-Marcille BM, Le Gouill S, Moreau P, Mohty M, Chevallier P.

Exp Hematol. 2014 Nov;42(11):945-54. doi: 10.1016/j.exphem.2014.07.264. Epub 2014 Jul 26.

PMID:
25072620
24.

Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.

Touzot M, Couvrat-Desvergnes G, Castagnet S, Cesbron A, Renaudin K, Cantarovich D, Giral M.

Transplantation. 2015 Jan;99(1):63-8. doi: 10.1097/TP.0000000000000285.

PMID:
25029384
25.

Emerging drugs of abuse: current perspectives on substituted cathinones.

Paillet-Loilier M, Cesbron A, Le Boisselier R, Bourgine J, Debruyne D.

Subst Abuse Rehabil. 2014 May 26;5:37-52. doi: 10.2147/SAR.S37257. eCollection 2014. Review.

26.

Characterization of antigen-specific B cells using nominal antigen-coated flow-beads.

Degauque N, Elong Ngono A, Akl A, Lepetit M, Crochette R, Giral M, Lepourry J, Pallier A, Castagnet S, Dugast E, Guillot-Gueguen C, Jacq-Foucher M, Saulquin X, Cesbron A, Laplaud D, Nicot A, Brouard S, Soulillou JP.

PLoS One. 2013 Dec 30;8(12):e84273. doi: 10.1371/journal.pone.0084273. eCollection 2013. Erratum in: PLoS One. 2014;9(7):e102845. Ngono, Annie Elong [corrected to Elong Ngono, Annie].

27.

Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation.

David G, Djaoud Z, Willem C, Legrand N, Rettman P, Gagne K, Cesbron A, Retière C.

J Immunol. 2013 Nov 1;191(9):4778-88. doi: 10.4049/jimmunol.1301580. Epub 2013 Sep 27.

28.

Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss.

Giral M, Foucher Y, Dufay A, Van Huyen JP, Renaudin K, Moreau A, Philippe A, Hegner B, Dechend R, Heidecke H, Brouard S, Cesbron A, Castagnet S, Devys A, Soulillou JP, Dragun D.

Am J Transplant. 2013 Oct;13(10):2567-76. doi: 10.1111/ajt.12397. Epub 2013 Aug 6.

29.

Amplified NKG2C+ NK cells in cytomegalovirus (CMV) infection preferentially express killer cell Ig-like receptor 2DL: functional impact in controlling CMV-infected dendritic cells.

Djaoud Z, David G, Bressollette C, Willem C, Rettman P, Gagne K, Legrand N, Mehlal S, Cesbron A, Imbert-Marcille BM, Retière C.

J Immunol. 2013 Sep 1;191(5):2708-16. doi: 10.4049/jimmunol.1301138. Epub 2013 Aug 5.

30.

Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient.

Ryckewaert A, Allain-Launay E, Moreau A, Blancho G, Cesbron A, Blin N, Roussey G.

Pediatr Transplant. 2013 Sep;17(6):E131-6. doi: 10.1111/petr.12113. Epub 2013 Jul 9.

PMID:
23834525
31.

Metallic profile of whole blood and plasma in a series of 106 healthy volunteers.

Cesbron A, Saussereau E, Mahieu L, Couland I, Guerbet M, Goullé JP.

J Anal Toxicol. 2013 Sep;37(7):401-5. doi: 10.1093/jat/bkt046. Epub 2013 Jun 21.

PMID:
23794607
32.

Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation.

Morishima Y, Kawase T, Malkki M, Morishima S, Spellman S, Kashiwase K, Kato S, Cesbron A, Tiercy JM, Senitzer D, Velardi A, Petersdorf EW; International Histocompatibility Working Group in Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1197-203. doi: 10.1016/j.bbmt.2013.05.020. Epub 2013 Jun 6.

33.

16th IHIW: international histocompatibility working group in hematopoietic cell transplantation.

Petersdorf EW, Malkki M, Hsu K, Bardy P, Cesbron A, Dickinson A, Dubois V, Fleischhauer K, Kawase T, Madrigal A, Morishima Y, Shaw B, Spellman S, Spierings E, Stern M, Tiercy JM, Velardi A, Gooley T; International Histocompatibility Working Group in Hematopoietic Cell Transplantation.

Int J Immunogenet. 2013 Feb;40(1):2-10. doi: 10.1111/iji.12022. Epub 2012 Dec 28.

34.

The natural history of clinical operational tolerance after kidney transplantation through twenty-seven cases.

Brouard S, Pallier A, Renaudin K, Foucher Y, Danger R, Devys A, Cesbron A, Guillot-Guegen C, Ashton-Chess J, Le Roux S, Harb J, Roussey G, Subra JF, Villemain F, Legendre C, Bemelman FJ, Orlando G, Garnier A, Jambon H, Le Monies De Sagazan H, Braun L, Noël C, Pillebout E, Moal MC, Cantarell C, Hoitsma A, Ranbant M, Testa A, Soulillou JP, Giral M.

Am J Transplant. 2012 Dec;12(12):3296-307. doi: 10.1111/j.1600-6143.2012.04249.x. Epub 2012 Sep 13.

35.

Pretransplant HLA mistyping in diagnostic samples of acute myeloid leukemia patients due to acquired uniparental disomy.

Dubois V, Sloan-Béna F, Cesbron A, Hepkema BG, Gagne K, Gimelli S, Heim D, Tichelli A, Delaunay J, Drouet M, Jendly S, Villard J, Tiercy JM.

Leukemia. 2012 Sep;26(9):2079-85. doi: 10.1038/leu.2012.68. Epub 2012 Mar 14.

PMID:
22488219
36.

Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors.

Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Flandrois G, Devys A, Stocco V, Cesbron A, Dehaut F, Moreau P, Harousseau JL, Mohty M.

Bone Marrow Transplant. 2009 Nov;44(9):613-5. doi: 10.1038/bmt.2009.60. Epub 2009 Mar 23. No abstract available.

PMID:
19308036
37.

Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.

Mai HL, Cesbron A, Brouard S, Blanchol G, Cantarovich D, Dantal J, Hourmant M, Lino M, Meurette A, Gosselin M, Abbadie O, Soulillou JP, Giral M.

Clin Transpl. 2009:361-8. No abstract available.

PMID:
20524299
38.

Specific humoral rejection of a pancreas allograft in a recipient of pancreas after kidney transplantation.

Carbajal R, Karam G, Renaudin K, Maillet F, Cesbron A, Rostaing L, Cantarovich D, Soulillou JP, Blancho G.

Nephrol Dial Transplant. 2007 Mar;22(3):942-4. Epub 2007 Jan 8. No abstract available.

PMID:
17210592
39.

[Microbeads, nanobeads and cytometry: applications to the analysis and purification of cells and biomolecules].

Lizard G, Duvillard L, Wedemeyer N, Muller C, Ghiringhelli F, Cesbron A, Poncelet P, Gallet F, Kahn E, Gambert P, Göhde W.

Pathol Biol (Paris). 2003 Sep;51(7):418-27. French.

PMID:
12948764
40.

Relevance of KIR gene polymorphisms in bone marrow transplantation outcome.

Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F, Chéneau ML, Schleinitz N, Cesbron A, Folléa G, Harrousseau JL, Bignon JD.

Hum Immunol. 2002 Apr;63(4):271-80.

PMID:
12039408
41.

Management of platelet and RhD maternal immunizations by PCR phenotypings after early amniocentesis.

Sagot P, Bonneville F, Bignon JD, Cesbron A, Boog G, Muller JY.

Fetal Diagn Ther. 1995 Nov-Dec;10(6):373-80.

PMID:
8579775
42.

Lack of evidence for a role of HLA-DP in unexplained recurrent spontaneous abortion.

Sagot P, Bignon J, Cesbron A, Cheneau ML, Boog G, Muller JY.

Transfus Clin Biol. 1995;2(3):145-50.

PMID:
7627354
43.

Susceptibility to alloimmunization to platelet HPA-1a antigen involves TAP1 polymorphism.

Braud V, Chevrier D, Cesbron A, Bignon JD, Kaplan C, Valentin N, Muller JY.

Hum Immunol. 1994 Oct;41(2):141-5.

PMID:
7860359
44.

HLA-DP and allogeneic bone marrow transplantation.

Moreau P, Cesbron A.

Bone Marrow Transplant. 1994 Jun;13(6):675-81. Review.

PMID:
7920290
45.

Lack of binding of peptides carrying the human platelet antigen 1 (HPA-1) dimorphism to purified HLA-DRw52a molecules.

Braud V, Valentin N, Choppin J, Cesbron A, Bignon JD, Blanchard D, Muller JY.

Rev Fr Transfus Hemobiol. 1993 Oct;36(5):439-49.

PMID:
7505078
46.

[Immunologic aspects of bone marrow transplantation].

Cesbron A, Moreau P, Muller JY.

Rev Fr Transfus Hemobiol. 1993 Jul;36(4):339-73. Review. French.

PMID:
8357446
47.

A monospecific HLA-B27 fluorescein isothiocyanate-conjugated monoclonal antibody for rapid, simple and accurate HLA-B27 typing.

Pei R, Arjomand-Shamsai M, Deng CT, Cesbron A, Bignon JD, Lee JH.

Tissue Antigens. 1993 Apr;41(4):200-3. No abstract available.

PMID:
8362412
48.

[Kidney transplantation and HLA-DR compatibility evaluated by genomic analysis: one center study].

Nataf S, Hourmant MH, Herry P, Cesbron A, Bonneville F, Cheneau ML, Muller JY, Soulillou JP, Bignon JD.

Rev Fr Transfus Hemobiol. 1993 Apr;36(2):179-89. French.

PMID:
8099286
49.

Crucial role of the third and fourth hypervariable regions of HLA-DPB1 allelic sequences in primary mixed-lymphocyte reaction: application in allogeneic bone marrow transplantation.

Cesbron A, Moreau P, Cheneau ML, Cury S, Milpied N, Muller JY, Harousseau JL, Bignon JD.

Transplant Proc. 1993 Feb;25(1 Pt 2):1232-3. No abstract available.

PMID:
8442098
50.

HLA-DR matching assessed by DNA analysis in kidney transplantation--a one-center study.

Bignon JD, Nataf S, Hourmant M, Cesbron A, Soulillou JP, Muller JY.

Transplant Proc. 1993 Feb;25(1 Pt 1):217-9. No abstract available.

PMID:
8094910

Supplemental Content

Loading ...
Support Center